We are live on ! Find out more
CC

Caxton Corporation Portfolio holdings

AUM $4.02M
1-Year Est. Return 256.08%
This Fund
S&P 500
This Quarter Est. Return
-20.61%
1 Year Est. Return
+256.08%
3 Year Est. Return
+777.99%
5 Year Est. Return
+744.68%
10 Year Est. Return
+18,621.85%
AUM
$83.8M
AUM Growth
-$3.11M
Cap. Flow
+$20.4M
Cap. Flow %
24.36%
Top 10 Hldgs %
97.64%
Holding
23
New
13
Increased
4
Reduced
2
Closed
3

Top Buys

Rank Stock Value
1
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$16.8M
2
ACAS
American Capital Ltd
ACAS
+$953K
3
ESL
Esterline Technologies
ESL
+$803K
4
ST icon
Sensata Technologies
ST
+$566K
5
RLYP
RELYPSA INC COM
RLYP
+$404K

Top Sells

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$1.22M
2
SLRC icon
SLR Investment Corp
SLRC
+$198K
3
PSEC icon
Prospect Capital
PSEC
+$158K
4
ICMB icon
Investcorp Credit Management BDC
ICMB
+$124K
5
AGRX
Agile Therapeutics
AGRX
+$35.1K

Sector Composition

Rank Sector Weight
1 Healthcare 86.3%
2 Technology 1.7%
3 Financials 0.91%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDGL icon
1
Madrigal Pharmaceuticals
MDGL
$12.6B
$71.9M 85.78%
1,058,804
+196,006
+23% +$16.8M
CPXX
2
DELISTED
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
$5.55M 6.62%
2,246,469
– –
ACAS
3
DELISTED
American Capital Ltd
ACAS
$962K 1.15%
+65,055
New +$953K
ESL
4
DELISTED
Esterline Technologies
ESL
$813K 0.97%
+7,107
New +$803K
ST icon
5
Sensata Technologies
ST
$6.46B
$611K 0.73%
+10,634
New +$566K
XBI icon
6
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.4B
$571K 0.68%
+7,596
New +$531K
RLYP
7
DELISTED
RELYPSA INC COM
RLYP
$405K 0.48%
+11,210
New +$404K
PHD
8
DELISTED
Pioneer Floating Rate Fund
PHD
$382K 0.46%
+32,874
New +$375K
ESPR
9
DELISTED
Esperion Therapeutics
ESPR
$340K 0.41%
+3,671
New +$237K
PSEC icon
10
Prospect Capital
PSEC
$1.17B
$309K 0.37%
36,527
-18,485
-34% -$158K
MDLY
11
DELISTED
Medley Management Inc
MDLY
$305K 0.36%
+2,776
New +$317K
EVF
12
Eaton Vance Senior Income Trust
EVF
$90.3M
$297K 0.35%
45,659
+30,256
+196% +$193K
PFX icon
13
PhenixFIN
PFX
$80.3M
$292K 0.35%
1,598
+773
+94% +$144K
AGRX
14
DELISTED
Agile Therapeutics
AGRX
$248K 0.3%
13
-2
-13% -$35.1K
BGX
15
Blackstone Long-Short Credit Income Fund
BGX
$137M
$224K 0.27%
+13,909
New +$220K
NSL
16
DELISTED
NUVEEN SENIOR INCM FD
NSL
$198K 0.24%
29,777
+18,775
+171% +$124K
OXSQ icon
17
Oxford Square Capital
OXSQ
$165M
$164K 0.2%
+23,742
New +$175K
FRA icon
18
BlackRock Floating Rate Income Strategies Fund
FRA
$382M
$152K 0.18%
+10,958
New +$149K
TLPH icon
19
Talphera
TLPH
$70.1M
$84K 0.1%
+1,094
New +$143K
TBRA
20
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
$14K 0.02%
+1,259
New +$13.5K
ALKS icon
21
Alkermes
ALKS
$8.66B
– –
-20,825
Closed -$1.22M
ICMB icon
22
Investcorp Credit Management BDC
ICMB
$12.4M
– –
-11,338
Closed -$124K
SLRC icon
23
SLR Investment Corp
SLRC
$725M
– –
-11,002
Closed -$198K

Similar funds

PCM
Pathway Capital Management Irvine, California $4.3M AUM 62.8% 1-Year Est. Return
EAMS
Eurizon Asset Management Slovakia Bratislava $3.4M AUM
RCP
RPM Capital Partners New York $3.34M AUM 43.17% 1-Year Est. Return
RA
Ritter Alpha New York $4.78M AUM
CGA
Compound Global Advisors Mercer Island, Washington $3.22M AUM 30.08% 1-Year Est. Return
HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
ABA
American Beacon Advisors Irving, Texas $5.08M AUM 20.11% 1-Year Est. Return
UOMF
University of Maryland Foundation Adelphi, Maryland $5.1M AUM 10.69% 1-Year Est. Return

Caxton Corporation's Q1 2015 Portfolio in Review

As of Q1 2015, Caxton Corporation held 23 positions worth $83.8M, down 3.6% from $86.9M the previous quarter. Its ten largest holdings account for 98% of the portfolio.

Caxton Corporation deployed $20.4M of net new capital in Q1 2015, opening 13 new positions and adding to 4 existing holdings. Its largest new stake was American Capital Ltd: 65,055 shares worth $962K.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 93% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was Prospect Capital, an estimated $158K trimmed.

  • Caxton Corporation's largest Q1 2015 buy was American Capital Ltd: 65,055 shares worth $962K.
  • Caxton Corporation added most to Madrigal Pharmaceuticals in Q1 2015, an estimated $16.8M increase.
  • Caxton Corporation's biggest Q1 2015 reduction was Prospect Capital, cutting an estimated $158K.
  • Caxton Corporation fully exited Alkermes in Q1 2015, selling an estimated $1.22M.
  • Caxton Corporation's ten largest holdings make up 98% of its $83.8M portfolio in Q1 2015.
  • Caxton Corporation opened 13 new positions and closed 3 in Q1 2015.
  • Caxton Corporation's portfolio value fell 3.6% quarter-over-quarter to $83.8M.

Based on Caxton Corporation's 13F filing for Q1 2015, filed 15 May 2015.